Comparison of General Anesthesia Hemodynamics Between R and P in Patients Undergoing Laparoscopic Hepatectomy

NCT06714669 | Completed Phase 3

• 1 other identifier: Zhongguo Zhou
• Study Type: interventional
• Target: 88
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a randomized controlled trial designed to investigate the effects of two anesthetics, remimazolam and propofol, on intraoperative hemodynamics in patients undergoing laparoscopic liver resection. The experimental group receives remimazolam, while the control group receives propofol. The primary objective is to compare the hemodynamic responses of patients in both groups during the surgical procedure, aiming to provide insights into the potential differences in cardiovascular stability and anesthetic management associated with these two drugs

Conditions

Hypotension During Surgery

Keywords

hypotension; hemodynamics; general anesthesia; remimazolam; propofol

Outcome Measures

Primary Outcomes (3)

• Blood pressure

  The primary focus is to evaluate and compare the impact of Remimazolam and Propofol on hemodynamic parameters such as blood pressure (both systolic and diastolic). The objective is to assess whether Remimazolam causes less hemodynamic fluctuation compared to Propofol during the induction and maintenance of general anesthesia.

  From enrollment to the end of treatment at 4 weeks

• Heart rate

  The primary focus is to evaluate and compare the impact of Remimazolam and Propofol on hemodynamic parameters such as heart rate. The objective is to assess whether Remimazolam causes less hemodynamic fluctuation compared to Propofol during the induction and maintenance of general anesthesia.

  From enrollment to the end of treatment at 4 weeks

• Mean arterial pressure

  The primary focus is to evaluate and compare the impact of Remimazolam and Propofol on hemodynamic parameters such as mean arterial pressure. The objective is to assess whether Remimazolam causes less hemodynamic fluctuation compared to Propofol during the induction and maintenance of general anesthesia.

  From enrollment to the end of treatment at 4 weeks

Study Arms (2)

Experimental Arm: Remimazolam Group

EXPERIMENTAL

Experimental Group (Remimazolam Anesthesia Arm): Patients in this arm will receive Remimazolam as the primary anesthetic agent for inducing and maintaining general anesthesia. The specific dosing regimen and administration protocol for Remimazolam will be determined based on the patient's characteristics and the surgical procedure being performed. Close monitoring of the patient's vital signs, particularly hemodynamic parameters, will be conducted throughout the anesthesia period to ensure safety and efficacy.

Drug: Remimazolam

Control Arm: Propofol Group

ACTIVE COMPARATOR

Control Group (Propofol Anesthesia Arm): Patients in this arm will receive Propofol as the primary anesthetic agent for general anesthesia. Propofol is a well-established anesthetic drug commonly used in clinical practice for its rapid onset and short duration of action. Similar to the experimental group, the dosing regimen and administration protocol for Propofol will be tailored to the individual patient's needs and the surgical procedure. Hemodynamic stability and other vital signs will also be closely monitored in this group to assess the safety and effectiveness of Propofol in comparison to Remimazolam.

Drug: propofol

Interventions

propofol DRUG

Control Group (Propofol Anesthesia Arm): Patients in this arm will receive Propofol as the primary anesthetic agent for general anesthesia. Propofol is a well-established anesthetic drug commonly used in clinical practice for its rapid onset and short duration of action. Similar to the experimental group, the dosing regimen and administration protocol for Propofol will be tailored to the individual patient's needs and the surgical procedure. Hemodynamic stability and other vital signs will also be closely monitored in this group to assess the safety and effectiveness of Propofol in comparison to Remimazolam.

Control Arm: Propofol Group

Remimazolam DRUG

Experimental Group (Remimazolam Anesthesia Arm): Patients in this arm will receive Remimazolam as the primary anesthetic agent for inducing and maintaining general anesthesia. Remimazolam belongs to a new class of benzodiazepines and acts by enhancing the activity of GABAA receptors, leading to sedation and anesthesia. The specific dosing regimen and administration protocol for Remimazolam will be determined based on the patient's characteristics and the surgical procedure being performed. Close monitoring of the patient's vital signs, particularly hemodynamic parameters, will be conducted throughout the anesthesia period to ensure safety and efficacy.

Experimental Arm: Remimazolam Group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Scheduled for LMH;
• Age 18-80 years, BMI 18-28 kg/m2;
• American Association of Anesthesiologists（ASA）I-III;
• Child-Pugh grade A or B;
• No serious heart, brain and other important organ lesions;
• Informed and consent, and signed informed consent.

You may not qualify if:

• ASA IV-V or Child-Pugh C;
• Left ventricular ejection fraction (EF) \<30%;
• Implanted with temporary or permanent pacemakers;
• Organic heart disease;
• Uncontrolled hypertension, diabetes and other chronic diseases;
• Prolonged use of sedative and analgesic drugs (such as opioid analgesics, benzodiazepines, antianxiety, antidepressants, antipsychotics, etc.);
• Alcohol addiction;
• Allergic to benzodiazepines or propofol, or to any ingredient in the studied drug;
• Known history of allergy to other anesthetics; difficulty in airway and intubation during induction.

Sponsors & Collaborators

• Sun Yat-sen University: lead

Study Sites (1)

Sun Yat-san University Cancer Center

Guangzhou, Guangdong, 510080, China

Location

MeSH Terms

Conditions

Hypotension

Interventions

Propofol; remimazolam

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, CARE PROVIDER
• Masking Details: In order to ensure the management of perioperative anesthesia and the safety of patients, this study is a single-blind study, that is, anesthesiologists know what kind of anesthesia they have received, and carry out anesthesia plans for patients according to groups (group P / R). Participants and postoperative evaluators will not know the grouping of patients.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Model Details: participants in the experimental group used remimazolam as intravenous anesthetics while participants in the control group used propofol.

Study Record Dates

• First Submitted: November 22, 2024
• First Posted: December 3, 2024
• Study Start: June 20, 2024
• Primary Completion: October 20, 2024
• Study Completion: October 30, 2024
• Last Updated: December 3, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)